This includes the use of externally validated thresholds for most imaging and tau biomarkers (e.g. CSF, ptau181, molecular PET imaging) and deriving optimal thresholds for hippocampal atrophy and the IMT ratio in the ADNI cohort rather than Mayo. The gene discussed is MAPT; the disease is hippocampal atrophy.